AbbVie's application for its wrinkle drug TrenibotE received a Complete Response Letter (CRL) from the FDA requesting more manufacturing details, but no safety or efficacy concerns were noted. The FDA did not require additional clinical trials, and AbbVie plans to respond thoroughly in the coming months. Meanwhile, AbbVie is investing $1.4 billion to build a new pharmaceutical manufacturing campus in North Carolina, aiming to enhance production with advanced technology and AI. This investment is part of a larger $100 billion commitment to U.S. research and manufacturing over the next decade.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
